PPARG and diabetes mellitus: Though the feasibility of therapeutically targeting the MPC in vivo in humans has yet to be fully tested, we note that PPARγ-sparing thiazolidinedione-like molecules that inhibit the MPC attenuate diabetes in rodents and are now being tested in humans (Colca et al., 2018; McCommis et al., 2015; McCommis et al., 2017).